Pharmacy Utilization Meeting

July 22, 2022

* Reviewed proposed pharmacy data items. The fields are broken up into two sets:

|  |
| --- |
| **Pharmacy Summary Data Items** |
| Pharmacy Hormone Flag | This flag indicates whether there is a pharmacy fill for an agent identified as a known first course therapy (FCOT) hormone treatment for patient's cancer. |
| List of NDC Codes | List of the hormone agent NDC codes the patient received that have been classified as FCOT for the specific cancer type. |
| Initial Hormone Dispense Date | Earliest dispense date of a FCOT hormone treatment that is a known treatment for the patient's cancer. |
| Latest Hormone Dispense Date | Latest dispense date of a FCOT hormone treatment that is a known treatment for the patient's cancer |
| Number of Monthly Fills | Total number of months patient was prescribed hormone treatments. |

* + Fields for other modalities could be added. Hormone is the initial focus given its prevalence over the other modalities in the pharmacy data.
	+ SAS data sets with the data items in the above table were computed using November 2021 submission data for Georgia and Idaho. Jennifer provided these data sets to the respective registries.

|  |
| --- |
| **Augmented CTC Data Items** |
| **NAACCR Item Number** | **Item Name** | **SEER PHAR Item** | **Business Rule** |
| 1220 | PHAR-RX Date Chemo | PHAR-RX Date Chemo | If dispensing event determined to be FCOT, then compare date against RX Date Chemo, take the earliest of the two |
| 1230 | PHAR-RX Date Hormone | PHAR-RX Date Hormone | If dispensing event determined to be FCOT, then compare date against RX Date Hormone, take the earliest of the two |
| 1240 | PHAR-RX Date BRM | PHAR-RX Date BRM | If dispensing event determined to be FCOT, then compare date against RX Date BRM, take the earliest of the two |
| 1260 | PHAR-Date Initial RX SEER | PHAR-Date Initial RX SEER | The earliest of Date Initial RX SEER and PHAR-RX Date Systemic |
| 1285 | PHAR-RX Summ--Treatment Status | PHAR-RX Summ--Treatment Status | Update RX Summ--Treatment Status from 0 (No), 2(AS) or 9 (Unknown) to 1(treatment given) if any of the PHAR-RX SUMM indicate treatment |
| 1390 | PHAR-RX Summ--Chemo | PHAR-RX Summ--Chemo | Business rules to determine if FTOC occurred based comparison RX Summ Chemo code; comparison of treatment date vs dx date; comparison of NDC and Generic Name vs. SEER\*Rx and NCCN; may update 00 or 99 to 01 |
| 1400 | PHAR-RX Summ--Hormone | PHAR-RX Summ--Hormone | Business rules to determine if FTOC occurred based comparison RX Summ Hormone code; comparison of treatment date vs dx date; comparison of NDC and Generic Name vs. SEER\*Rx and NCCN; may update 00 or 99 to 01 |
| 1410 | PHAR-RX Summ--BRM | PHAR-RX Summ--BRM | Business rules to determine if FTOC occurred based comparison RX Summ BRM code; comparison of treatment date vs dx date; comparison of NDC and Generic Name vs. SEER\*Rx and NCCN; may update 00 or 99 to 01 |
| 1632 | PHAR-Neoadjuvant Therapy | PHAR-Neoadjuvant Therapy | Code PHAR-Neoadjuvant Therapy = 2 when Neoadjuvant Therapy is 0 or 9 and PHAR-RX SUMM is not 0 or 9 and PHAR-RX Date Systemic is greater than or equal to 60 days before Surgery Date |
| 1639 | PHAR-RX Summ--Systemic/Sur Seq | PHAR-RX Summ--Systemic/Sur Seq | Recalculate PHAR-RX Summ--Systemic/Sur Seq based on Date Surgery and PHAR-RX Date Systemic |
| 1750 | PHAR-Date of Last Contact | PHAR-Date of Last Contact | Update based on last known Medication Dispense Date - we decided to drop since we currently update patient set DOLC with pharmacy data |
| 3230 | PHAR-RX Date Systemic | PHAR-RX Date Systemic | The earliest of RX Date Systemic, PHAR-RX Date Chemo, PHAR-RX Date Hormone, PHAR-RX Date BRM |
| - | PHAR-Dispense Events Cumulative | PHAR-Dispense Events Cumulative | Number of dispensing events per patient (should it be per case?) |
| - | PHAR-Dispense Quantity Cumulative | PHAR-Dispense Quantity Cumulative | Summ of values in the Dispense Quantity field |
| - | PHAR-Dispense Duration Cumulative | PHAR-Dispense Duration Cumulative | Sum of all Dispense Duration Events |
| - | PHAR-Dispense Period Starts | PHAR-Dispense Period Starts | Time (Days) from DX date to first dispensing event |
| - | PHAR-Dispense Period Starts | PHAR-Dispense Period Starts | Time (Days) from DX date to last dispensing event |
| - | PHAR- Chemo No FCOT Flag | PHAR- Chemo No FCOT Flag | Chemo treatment deemed to not to be FCOT reported (flags treatment that is dispensed beyond 365 days or is not indicated as first line) |
| - | PHAR- Hormone No FCOT Flag | PHAR- Hormone No FCOT Flag | Hormone treatment deemed to not to be FCOT reported (flags treatment that is dispensed beyond 365 days or is not indicated as first line) |
| - | PHAR- BRM No FCOT Flag | PHAR- BRM No FCOT Flag | BRM treatment deemed to not to be FCOT reported (flags treatment that is dispensed beyond 365 days or is not indicated as first line) |

* + Don’t include PHAR-Date of Last Contact. Pharmacy Data updates Date of Last Contact on the patient set already.
* Jennifer: Do we update values that indicate refusal of treatment (82-87) to 01 if they have pharmacy transactions indicating they received the drugs?
* Randi: Reviewed Idaho datasets for patients that indicated they refused hormone treatment. She recommended that a patient have received more than 1 pharmacy transaction in order to update pharmacy fields to 01.
* It was decided that we should extend this requirement to all values, including 00 and 99. Only update Rx Summ fields to 01 if there is more than 1 pharmacy transaction. This will help screen out patients that only received a treatment once but did not pickup the treatment or take the treatment.
* **Action item**: David and Jennifer will work on analysis to see how many patients received only a single pharmacy transaction.
* Jennifer created data sets for frequencies of immunotherapy and chemotherapy agents by SEER Site Group. We created a similar list for hormone therapy when we were trying to select the first course therapy agents for hormone. We used the hormone dataset to determine which sites are primarily treated with hormone. Lois Dickie at NCI then reviewed the sites we selected and determined the first course of therapy agents for those sites.
* We reviewed the lists. Serban suggested that we use the same sites we selected for hormone treatment in order to give a complete treatment profile for these sites. The sites we selected for hormone were
	+ Breast
	+ Prostate
	+ Leukemias
	+ Corpus Uteri
	+ Myeloma
	+ Lymphomas
	+ Ovary
	+ Endocrine Systems – Lois did not generate a first course of therapy list for endocrine given the difficulty of doing this for hormone treatments for endocrine.
* **Action item:** Jennifer will create files of frequencies of chemotherapy and immunotherapy agents for these sites that Lois can then review for first course treatments.